As of July 1, Spanish pharmacies will begin to distribute Mounjaro, a new medicine to treat obesity and type 2 diabetes. Mounjaro, with strzpatid as an active substance, stands out for their ability to stimulate two hormones that regulate blood sugarand reduce appetite, thus improving the results of previous treatments such as Ozempic or Wegovy.
Although approved by the European Medicines Agency, Mounjaro will not be funded by the Ministry of Health, which makes it more expensive.The 5MG treatment will cost 271 euros and 10mg, 358 euros.Its administration is through a weekly injection, starting with a dose of 2.5mg and adjusting according to the results.
Clinical trials have shown that Mounjaro achieves glycemic control in more than 90% of patients and a significant weight reduction, with an average of 22.5% in obese patients.To acquire it in pharmacies, medical recipe will be necessary.